Dear Investors,
EnteroBiotix is advancing a new generation of microbiome-based therapeutics, with its lead program now entering Phase 2b development for irritable bowel syndrome (IBS).
Join Opus8 and New York Private Equity Forums (NYPEF) for an exclusive investor briefing featuring EnteroBiotix and EBX-102-02®, an investigational oral therapy being developed for IBS-C.
Following positive Phase 2a results, EnteroBiotix has advanced EBX-102-02 into Phase 2b, with its RISE study now underway in approximately 300 patients. Topline efficacy data are anticipated in H2 2027.
Why Investors Are Taking Notice
Clinical Momentum: Positive Phase 2a results followed by a 300-patient Phase 2b study.
Large Patient Population: IBS affects approximately 11% of the global population, with more than $10B in direct annual U.S. healthcare costs.
Recent Financing: EnteroBiotix raised £19M ($25M) to advance EBX-102-02 into Phase 2b.
Broader Pipeline: Additional microbiome programs are being developed in liver disease and blood cancer.
Learn more about EnteroBiotix, its clinical progress, and the development path for EBX-102-02.
